Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Private Formulations

This article was originally published in The Tan Sheet

Executive Summary

Private Formulations: Halts production of Medicine Shoppe Gas Relief Tab 24X100 and Simethicone 80 after 750 cases of the product were seized by the St. Louis District Attorney's office in November. FDA requested the seizure after it found that Edison, N.J.-based Private Formulations, the product manufacturer, failed to meet good manufacturing practices. Private Formulations was charged with failure to ensure proper validation of the product, failure to use appropriate testing procedures, failure to validate its test methods, and failure to adhere to an adequate stability program. Medicine Shoppe voluntarily withheld shipment of the product in mid-September upon FDA's request. The pills, priced at more than $28,500, were seized later at a public warehouse used by Medicine Shoppe...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS083612

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel